Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2019

01-10-2019 | Breast Cancer | Letter to the Editor

RE.: Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer

Authors: Sixten Harborg, Deirdre P. Cronin-Fenton, Signe Borgquist

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Login to get access

Excerpt

In a recent publication in Breast Cancer Research and Treatment, Li et al. investigated the association between long-term lipid-lowering therapy on clinical outcomes in patients with breast tumors. The study enrolled 1523 patients with ductal carcinoma in situ (DCIS) or invasive breast tumors. Use of statins for at least 5 years (n = 207) was associated with improved disease-free survival compared with nonusers. However, the association was not detected in patients who had been exposed to statins for less than 5 years. …
Literature
1.
2.
Hernán MA (2018) How to estimate the effect of treatment duration on survival outcomes using observational data. BMJ 360:k182CrossRefPubMed
3.
Harrell F (2015) Regression modeling strategies, 2nd edn. Springer International Publishing, Switzerland, p 582CrossRef
4.
Metadata
Title
RE.: Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer
Authors
Sixten Harborg
Deirdre P. Cronin-Fenton
Signe Borgquist
Publication date
01-10-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05337-2

Other articles of this Issue 3/2019

Breast Cancer Research and Treatment 3/2019 Go to the issue

Epidemiology

Domain-specific patterns of physical activity and risk of breast cancer sub-types in the MCC-Spain study

Clinical trial

The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry

Correction

Correction to: Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer

Clinical trial

Talking about risk in the context of genomic tests (TARGET): development and evaluation of an educational program for clinicians

Preclinical study

Breast pain and cancer: should we continue to work-up isolated breast pain?

Preclinical study

Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits